Joe Biden’s recent visit to Seattle Genetics has set the Puget Sound region’s cancer research community in the spotlight. Located in Bothell, Seattle Genetics is a Cancer Drug Company endeavored to widen the use of its first drug while developing new medicines. The move demonstrates Seattle Genetics’ ambitiousness and commitment to advancing cancer research community. Currently, Seattle Genetics is testing Adcetris, Seattle Genetics’ only commercialized drug in different cancer treatment scenarios. Seattle Genetics’ Chief Operating Officer, Clay Siegall noted that Adcetris is being tested in over 70 trials against various types of lymphomas. Adcetris is used in Phase 3 to treat previously and newly diagnosed Hodgkin lymphoma.
Siegall added that the results of Phase 3 trial would by far impact on the company’s reputation compared with other tests done this year. Last year, Adcetris generated almost $226 million in revenue in Canada, and the U.S combined. In the year 2016, its sales revenue is expected to be between $225 and $275 million. Besides, Seattle Genetics’ partner, Takeda Pharmaceutical will distribute the drug outside Canada, and the U.S. Seigall also pointed out that Adectris is one of the many drugs in Seattle Genetics’ store. Excluding Adcetris, Seattle Genetics is now developing 12 types of cancer drugs. The company intends to introduce another cancer drug, 33A, to Phase 3 clinical trials. The new drug will be used to treat acute myeloid leukemia.
Furthermore, Seattle Genetics plans to launch 12 new drugs. The company will invest heavily in those three drugs to find a cure for cancer. With 800 employees on board, Seattle Genetics is hiring more employees. It plans to add 100 and 20 employees in its offices in the U.S. and Switzerland respectively.
About Clay Siegall
Dr. Siegall serves as Seattle Genetics’ President and Chief Operating Officer. Besides, he serves as the Chairman of Board of Seattle Genetics. He holds a degree in Zoology from Maryland University and a Ph.D. in Genetics from George Washington University. Before Seattle Genetics, Siegall worked at the National Cancer Institute and Bristol-Myers Squibb Pharmaceuticals between 1988 and 1991.